在失去独家权之前,美国药品定价模式
Ching-Hsuan Lin1, Jonathan D Campbell2, James Motyka2
1Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA.
概括
药物价格在推出后经常下降,这与成本效益分析中常见的假设相反. 这项研究模拟了这些动态价格变化,以改善品牌药物的经济预测.
科学领域:
- 卫生经济学 卫生经济学
- 制药政策 制药政策
- 药物经济学 药物经济学
背景情况:
- 成本效益分析 (CEA) 往往假定药物在推出后的定价是静态的.
- 这种假设可能会导致由于典型的价格波动导致不准确的经济预测.
- 关于药物价格动态的经验数据有限,这阻碍了将现实的定价纳入CEA.
研究的目的:
- 描述品牌药品在上市后和在市场独家权丧失之前的通胀调整后价格变化.
- 开发和应用回归模型来预测药物价格轨迹.
- 为了确定影响药品价格变化的因素,在他们的生命周期.
主要方法:
- 对32种美国高消费品牌药物的通货膨胀调整后净价格数据的分析.
- 开发普通最小平方和线性混合效应回归模型.
- 根据文献审查和统计标准,识别和选择影响因素.
主要成果:
- 经通货膨胀调整后,药品价格的年平均变化为 -4.7% (中位数: -2.4%).
- 模型预测大多数药物类型的价格下降,除了医疗保险保护类药物外.
- 自药物推出以来,价格变化率倾向于随着时间的推移而适度.
结论:
- 大市场品牌药物的通货膨胀调整后价格通常在推出后下降,并且在独家性之前损失.
- 动态定价的实证建模提高了CEA的准确性.
- 结合可观察到的药物特征可以改进经济预测.
相关概念视频
Drug Nomenclature
1.5K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.5K
Prescription, Nonprescription and Orphan Drugs
665
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
665
Bioequivalence: Overview
890
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
890
Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
33
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
33
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
92
When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
92


